Drug Trial Radar · NCT00308711
Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor
Last checked: Nov 19, 2026Latest source record: Jun 25, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,308
Actual
Start
Apr 2006
Primary completion
Aug 2007
Study completion Aug 2007
Sponsor
- Lead sponsor
- Ferring PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Mar 30, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether the misoprostol vaginal insert (50 mcg and 100 mcg) can safely and effectively speed time to vaginal delivery compared to Cervidil (R) in women who need to have cervical ripneing and induction of labor.
Conditions
- Cervical Ripening
- Labor, Induced
Interventions
Misoprostol vaginal insert 100 mcgDrug
Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
Misoprostol vaginal insert 50 mcgDrug
Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
Dinoprostone vaginal insert (Cervidil)Drug
Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Minutes From Drug Insertion to Vaginal DeliveryTime frame: 2880 minutes
- Percentage of Participants With a Cesarean Section DeliveryTime frame: 2880 minutes
Locations
52 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Medical Center
Birmingham, Alabama
Banner Desert Medical Center
Mesa, Arizona
Maricopa Medical Center
Phoenix, Arizona
Arizona Wellness Center for Women
Phoenix, Arizona
Tuscon Medical Center
Tucson, Arizona
Long Beach Memorial Medical Center
Long Beach, California
UCI Medical Center
Orange, California
Santa Clara Valley Medical Center
San Jose, California
Christiana Care Health System
Newark, Delaware
Bayfront Medical Center
St. Petersburg, Florida
University of Florida Health Sciences Center
Tampa, Florida
St. Mary's Medical Center
West Palm Beach, Florida
Northside Hospital
Alpharetta, Georgia
Hurley Medical Center
Flint, Michigan
University of Minnesota Medical Center
Minneapolis, Minnesota
St. Elizabeth Regional Medical Center
Lincoln, Nebraska
Morristown Memorial Hospital
Morristown, New Jersey
University of New Mexico Medical Center
Albuquerque, New Mexico
United Health Services Hospitals, Inc.
Johnson City, New York
Winthrop-South Nassau University Health Center
Mineola, New York
NYU School of Medicine
New York, New York
Columbia University Medical Center
New York, New York
Jacobi Medical Center
The Bronx, New York
Women's Health Alliance
Winston-Salem, North Carolina
University of Cincinnati Holmes Hospital
Cincinnati, Ohio
Ohio State University Medical Center
Columbus, Ohio
Miami Valley Hospital
Dayton, Ohio
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Legacy Center for Maternal-Fetal Medicine
Portland, Oregon
Abington Memorial Hospital
Abington, Pennsylvania
Lehigh Valley Medical Center
Allentown, Pennsylvania
Temple University Hospital
Philadelphia, Pennsylvania
University of Pittsburgh - Magee Women's Hospital
Pittsburgh, Pennsylvania
Lankenau Hospital
Wynnewood, Pennsylvania
Greenville Hospital System
Greenville, South Carolina
Trident Health System
North Charleston, South Carolina
Erlanger Hospital
Chattanooga, Tennessee
University of Tennesse Medical Center
Knoxville, Tennessee
Baptist Memorial Hospital
Memphis, Tennessee
Methodist Charlton Medical Center
Dallas, Texas
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.